Abstract
Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 269-272 |
Number of pages | 4 |
Journal | Journal of Oncology Pharmacy Practice |
Volume | 16 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2010 |
Externally published | Yes |
Keywords
- Yondelis
- hepatic
- renal
- sarcoma
- trabectedin
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)